DyneLogo_R_FINAL_FULL_COLOR_RGB.jpg
Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer
March 27, 2024 16:05 ET | Dyne Therapeutics, Inc.
WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for...
DyneLogo_R_FINAL_FULL_COLOR_RGB.jpg
Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium
March 27, 2024 08:30 ET | Dyne Therapeutics, Inc.
WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for...
John Cox
Dyne Therapeutics Announces CEO Transition
March 25, 2024 07:30 ET | Dyne Therapeutics, Inc.
- John Cox, Industry Leader with Global Experience in Rare Disease Commercialization, Joins Dyne as President and CEO - WALTHAM, Mass., March 25, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc....
DyneLogo_R_FINAL_FULL_COLOR_RGB.jpg
Dyne Therapeutics to Present at Stifel 2024 Virtual CNS Days
March 13, 2024 07:30 ET | Dyne Therapeutics, Inc.
WALTHAM, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for...
DyneLogo_R_FINAL_FULL_COLOR_RGB.jpg
Dyne Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
March 05, 2024 07:30 ET | Dyne Therapeutics, Inc.
- Positive Initial Clinical Data from ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients Demonstrated Proof-of-Concept, Validating the Promise of the FORCE™ Platform and Targeted Delivery...
DyneLogo_R_FINAL_FULL_COLOR_RGB.jpg
Dyne Therapeutics Announces Upcoming Presentations on Initial Clinical Data From its ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference
February 14, 2024 16:15 ET | Dyne Therapeutics, Inc.
- Presentations will Highlight Initial Data Announced in January 2024 Demonstrating Proof-of-Concept in its DM1 and DMD Programs, Validating the Promise of the FORCE™ Platform and Targeted Delivery to...
DyneLogo_R_FINAL_FULL_COLOR_RGB.jpg
Dyne Therapeutics to Present at February Investor Conferences
February 01, 2024 07:30 ET | Dyne Therapeutics, Inc.
WALTHAM, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for...
DyneLogo_R_FINAL_FULL_COLOR_RGB.jpg
Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
January 11, 2024 16:05 ET | Dyne Therapeutics, Inc.
WALTHAM, Mass., Jan. 11, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for...
DyneLogo_R_FINAL_FULL_COLOR_RGB.jpg
Dyne Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
January 05, 2024 07:30 ET | Dyne Therapeutics, Inc.
WALTHAM, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for...
DyneLogo_R_FINAL_FULL_COLOR_RGB.jpg
Dyne Therapeutics Announces Pricing of $300 Million Public Offering of Common Stock
January 04, 2024 22:46 ET | Dyne Therapeutics, Inc.
WALTHAM, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for...